Results 91 to 100 of about 231,717 (193)

Wild-Type Transthyretin Amyloid Cardiomyopathy With Positive

JACC: Case Reports
Background: Wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is increasingly recognized with advances in noninvasive imaging and disease-modifying therapies.
Aya Elalfy, DO, Zeyad Kholeif, MD, Rana Rashwan, MD, Carlos Vergara Sanchez, MD, Awais Malik, MD   +4 more
doaj   +1 more source

Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report

Journal of Medical Case Reports, 2018
Background Transthyretin amyloidosis is a systemic disorder caused by extracellular deposition of insoluble amyloid fibrils in peripheral and autonomic nerves, heart, kidney, gastrointestinal tract, and other organs.
Hiroyuki Yamamoto, Toru Hashimoto, Shunji Kawamura, Michiaki Hiroe, Taro Yamashita, Yukio Ando, Tomoki Yokochi   +6 more
doaj   +1 more source

Serum prealbumin and disease progression in patients with wild-type Transthyretin Cardiomyopathy on treatment with Tafamidis.

reservedSerum transthyretin (sTTR) is the precursor protein of wild type transthyretin amyloid cardiomyopathy (ATTRwt-CM) and the biological target of tafamidis.
BALDAN, MARCO
core  

Hereditary Transthyretin Amyloid Cardiomyopathy [PDF]

JAMA Cardiology, 2022
Quentin R, Youmans, Sanjiv J, Shah, Sadiya S, Khan   +2 more
openaire   +2 more sources

Cryo-EM structures of biopsy-derived TTR fibrils in hereditary transthyretin amyloidosis

Nature Communications
Hereditary transthyretin amyloidosis (ATTRv) is a fatal autosomal dominant disease characterized by systemic deposition of transthyretin (TTR) amyloid fibrils, leading to progressive neuropathy and cardiomyopathy.
Yuxin Zheng, Jiawei Liang, Zhenyu Li, Yixiao Liu, Xujun Chu, Shaochong Zhang, Wenjuan Wang, Jionglin Bao, Boyu Liu, Conghui Ma, Guowei Yin, Jianwen Deng, Wei Chi, Lingchao Meng, Yang Shi   +14 more
doaj   +1 more source

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy

Clinical Medicine Insights: Cardiology, 2017
Background: Transthyretin cardiomyopathy (TTR-CM) is a progressive, fatal disease caused by the accumulation of misfolded transthyretin (TTR) amyloid fibrils in the heart.
Marla B Sultan, Balarama Gundapaneni, Jennifer Schumacher, Jeffrey H Schwartz   +3 more
doaj   +1 more source

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care

Therapeutics and Clinical Risk Management, 2020
Marco Luigetti,1,2 Angela Romano,2 Andrea Di Paolantonio,2 Giulia Bisogni,3 Mario Sabatelli2,3 1Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 2Università Cattolica del Sacro Cuore, Rome, Italy; 3Centro ...
Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M   +4 more
doaj  

Sodium-glucose cotransporter 2 inhibitor use and outcomes in transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by myocardial deposition of misfolded transthyretin protein-forming amyloid fibrils which can result in symptomatic heart failure (HF).1 The only medication currently approved by the U.S.
Vikash Jaiswal (11613089), Tanisha Prasad (19419951), Robert J Mentz (21236281), Gregg C Fonarow (7324139), Muhammad Hanif (1737865), Akash Jaiswal (12073759), Muhammad Shahzeb Khan (21236278), Kripa Rajak (17918553), Yusra Mashkoor (20813441)   +8 more
core  

Effect of catheter ablation with vein of Marshall ethanol infusion for perimitral flutter in a patient with senile transthyretin cardiac amyloidosis: a case report

Frontiers in Cardiovascular Medicine
BackgroundSenile transthyretin cardiac amyloidosis (AL) is an underdiagnosed infiltrative cardiomyopathy causing heart failure symptoms in elderly patients.
Simon Fitouchi, Mickael Ohana, Thomas Cardi, Laurence Jesel, Laurence Jesel, Halim Marzak, Halim Marzak   +6 more
doaj   +1 more source

Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker Discovery

Biomedicines
Background/Objectives: Having serum biomarkers available for cardiac transthyretin amyloidosis (ATTR-CA) would be beneficial for diagnosis and prognosis. This study aimed to identify potential ATTR-CA biomarkers through proteomic analysis.
Joanna Waś, Monika Gawor-Prokopczyk, Agnieszka Sioma, Rafał Szewczyk, Aleksandra Pel, Jolanta Krzysztoń-Russjan, Magdalena Niedolistek, Dorota Sokołowska, Jacek Grzybowski, Łukasz Mazurkiewicz   +9 more
doaj   +1 more source